# Xycota Biosciences, LLC

> Xycota Biosciences is a preclinical central-nervous-system (CNS) biotechnology company developing a low-dose psilocybin capsule designed for at-home study in mild PTSD (XYCO-02) and a preclinical exosome-based candidate for Frontotemporal Dementia (XYCO-01).

- **Headquarters:** 30 N Gould St Ste R, Sheridan, WY 82801, USA
- **Website:** https://xycota.com
- **Regulatory Status:** All programs are investigational and preclinical. No Xycota candidate has been approved by the U.S. FDA, Health Canada, or any regulatory authority.

## Core Pages

- [Home](https://xycota.com/): Overview of Xycota's BDNF/TrkB repair-pathway approach, rat-to-human evidence transition, investigational pipeline, and scientific roster.
- [Science](https://xycota.com/science): Mechanism of action (BDNF/TrkB signaling and synaptic protein recovery) and summary of the peer-reviewed *Neuropsychopharmacology* (July 2026) rat study.
- [Pipeline](https://xycota.com/pipeline): Program details and regulatory milestones for XYCO-02 (mild PTSD; Health Canada Phase IIa CTA in preparation) and XYCO-01 (Frontotemporal Dementia; FDA Orphan Drug Designation under review).
- [Investors](https://xycota.com/investors): Corporate overview, investor briefing video, leadership & governance, and scientific publications.
- [PTSD Resources Hub](https://xycota.com/ptsd): Educational resources on trauma, veterans' perspectives featuring Lt. Col. Elton L. Johnson Jr. (U.S. Army, Ret.), and clinical trial literacy.
- [Free PTSD Companion](https://xycota.com/ptsd-app): Free, private, browser-local breathing, grounding, and appointment-readiness tool (non-medical educational utility).
- [Movement Ambassadors](https://xycota.com/ambassadors): Community and stakeholder briefing registration across Veteran/First Responder, Athlete/mTBI, and Clinical/Research tracks.
- [Institutional Data Room](https://xycota.com/data-room): Confidentiality-gated diligence portal for qualified institutional and strategic partners.
- [FAQs](https://xycota.com/faqs): Frequently asked questions covering scientific mechanism, clinical trial design, regulatory status, and corporate governance.
- [Insights](https://xycota.com/insights): Research commentary on sub-perceptual neuroplasticity, exosome blood-brain-barrier transport, and functional unblinding in clinical trials.

## Key Peer-Reviewed Publication

- **Ascone F, Trezza V, Hausman MS et al. (2026).** *Repeated low-dose psilocybin and BDNF/TrkB-dependent object-recognition memory in Fmr1-Δexon 8 rats.* **Neuropsychopharmacology** (Published July 2026). DOI: https://doi.org/10.1038/s41386-026-02361-x

## Leadership & Scientific Roster

- **Brad Listermann** : Co-Founder & CEO
- **Dr. Marvin S. Hausman, MD** : Chief Scientific Officer & Co-Founder
- **Associate Professor Viviana Trezza, PhD** : Associate Professor of Pharmacology, Roma Tre University (External Academic Collaborator)
- **Dr. Louise Hecker, PhD** : Preclinical Pharmacology & Behavioral Neuroscience Collaborator
- **Andrew Charrette** : Regulatory Affairs Advisor (Health Canada CTA & FDA submissions)
- **Lt. Col. Elton L. Johnson Jr. (U.S. Army, Ret.)** : Board Member & Veteran Advocate